BiotechTube
Home/Pipeline/Humira (Adalimumab) Biosimilar

Humira (Adalimumab) Biosimilar

Autoimmune Diseases

Early PreclinicalActive

Key Facts

Indication
Autoimmune Diseases
Phase
Early Preclinical
Status
Active
Company
NeuClone

About NeuClone

Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.

View full company profile

Therapeutic Areas

OncologyImmunologyBone HealthInfectious Diseases

Other Autoimmune Diseases Drugs

DrugCompanyPhase
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelAstellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial
I&I PortfolioThird Arc BioPre-clinical